{
    "clinical_study": {
        "@rank": "168169", 
        "arm_group": {
            "arm_group_label": "Treatment (ipilimumab and brentuximab vedotin)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive ipilimumab IV over 90 minutes on day 1 of courses 1-4, 8, 12, and 16 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of ipilimumab when given together\n      with brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma.\n      Monoclonal antibodies, such as ipilimumab and brentuximab vedotin, can block cancer growth\n      in different ways. Some block the ability of cancer cells to grow and spread. Others find\n      cancer cells and help kill them or carry cancer-killing substances to them."
        }, 
        "brief_title": "Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", 
        "condition": "Recurrent Adult Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the\n      combination of brentuximab vedotin and ipilimumab.\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate complete response (CR) rate, partial response (PR) rate and overall response\n      rate (ORR), for the combination of brentuximab vedotin and ipilimumab.\n\n      II. To evaluate the duration of remission (DOR) to the combination of brentuximab vedotin\n      and ipilimumab, and compare with the DOR achieved with the most recent prior systemic\n      therapy.\n\n      III. To evaluate the progression-free survival (PFS) and the overall survival (OS) in\n      patients receiving the combination of brentuximab vedotin and ipilimumab.\n\n      TERTIARY OBJECTIVES:\n\n      I. To evaluate the ability of the combination of brentuximab and ipilimumab to alter tumor\n      specific T cell immunity.\n\n      II. To evaluate a panel of cytokine and T cell specific biomarkers from the peripheral blood\n      as a potential immune signature of treatment response to therapy with brentuximab vedotin\n      and ipilimumab for patients with relapsed / refractory Hodgkin lymphoma (HL).\n\n      III. To evaluate using gene expression profiling (GEP) a signature of response to the novel\n      combination of an antibody drug conjugate with immunomodulatory therapy.\n\n      OUTLINE: This is a dose-escalation study of ipilimumab.\n\n      Patients receive ipilimumab intravenously (IV) over 90 minutes on day 1 of courses 1-4, 8,\n      12, and 16 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21\n      days for up to 16 courses in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have pathologically confirmed relapsed or refractory classical Hodgkin\n             lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including\n             lymphocyte predominant (LP) HL are not permitted\n\n          -  Patients must have relapsed after first line chemotherapy; may have relapsed after\n             autologous or allogeneic stem cell transplant, or have primary refractory disease; no\n             upper limit for number of prior therapies; if status post allogeneic stem cell\n             transplant, no active graft versus host disease\n\n          -  Patients may have received prior brentuximab vedotin, but must not have received\n             brentuximab vedotin within 6 months prior to registration, and must not have relapsed\n             within 6 months of receiving previous brentuximab vedotin; patients may not have\n             received prior ipilimumab\n\n          -  Patients may have received other prior immunotherapies, but must not have received\n             them within 6 months prior to registration, and there must be no serious unresolved\n             complication of therapy at the time of registration\n\n          -  Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging\n             Network (ACRIN) performance status between 0-2\n\n          -  Patients must have measurable disease; baseline measurements and evaluations must be\n             obtained within 4 weeks of registration to the study; abnormal positron emission\n             tomography (PET) scans will not constitute evaluable disease unless verified by a\n             diagnostic quality computed tomography (CT) scan; patients must use the same imaging\n             modality (CT or PET/CT) throughout the study\n\n          -  Women must not be pregnant or breast-feeding; all females of childbearing potential\n             must have a blood test or urine study within 2 weeks prior to registration to rule\n             out pregnancy\n\n          -  Women of childbearing potential and sexually active males must be strongly advised to\n             use an accepted and effective method of contraception or to abstain from sexual\n             intercourse for the duration of their participation in the study\n\n          -  Patients must have no evidence of dyspnea at rest, no exercise intolerance, and a\n             pulse oximetry > 92% while breathing room air\n\n          -  Patients must have forced expiratory volume in one second (FEV1)/forced vital\n             capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large\n             mediastinal mass from Hodgkin lymphoma (HL); carbon monoxide diffusion capacity\n             (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be\n             obtained within one month prior to registration\n\n          -  Absolute neutrophil count (ANC) >= 1500/mcL (1.5 x 10^9/L)\n\n          -  Platelets >= 75,000/mcL (75 x 10^9/L)\n\n          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit\n             of normal (ULN)\n\n          -  Bilirubin =< 2 x ULN (unless documented Gilbert's syndrome, for which bilirubin =< 3\n             x ULN is permitted)\n\n          -  Calculated creatinine clearance by Cockroft-Gault formula >= 30 ml/min\n\n          -  No evidence of prior malignancy except adequately treated non-melanoma skin cancer,\n             in situ cervical carcinoma or any surgically- or radiation-cured malignancy\n             continuously disease free for >= 5 years so as not to interfere with interpretation\n             of radiographic response\n\n          -  Patient must have no current or prior history of central nervous system (CNS)\n             involvement\n\n          -  All prior therapy must have been completed at least 21 days prior to enrollment; no\n             concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose\n             of treatment of lymphoma are allowed; topical steroids are allowed\n\n          -  No history of Steven's Johnson's syndrome, toxic epidermal necrolysis (TENs)\n             syndrome, or motor neuropathy\n\n          -  Human immunodeficiency virus (HIV) positive patients are allowed on this study if\n             they have a cluster of differentiation 4 (CD4) count > 400, and are on a stable\n             antiviral regimen; patients with poorly controlled HIV or other chronic active viral\n             infections will be excluded\n\n          -  Patients must not have autoimmune disorders or conditions of immunosuppression that\n             require current ongoing treatment with systemic corticosteroids (or other systemic\n             immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or\n             continuous use of topical steroid creams or ointments or ophthalmologic steroids; a\n             history of occasional (but not continuous) use of steroid inhalers is allowed\n\n               -  Replacement doses of steroids for patients with adrenal insufficiency are\n                  allowed; patients who discontinue use of these classes of medication for at\n                  least 2 weeks prior to randomization are eligible if, in the judgment of the\n                  treating physician investigator, the patient is not likely to require resumption\n                  of treatment with these classes of drugs during the study\n\n               -  Exclusion from this study also includes patients with a history of symptomatic\n                  autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis\n                  [scleroderma], systemic lupus erythematosus, Sj\u00f6gren's syndrome, autoimmune\n                  vasculitis [e.g., Wegener's granulomatosis]); motor neuropathy considered of\n                  autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other\n                  CNS autoimmune disease (e.g., poliomyelitis, multiple sclerosis); patients with\n                  autoimmune hypothyroid disease or type I diabetes on replacement treatment are\n                  eligible\n\n          -  Patients must not have grade 2 or greater peripheral sensory neuropathy\n\n          -  Patients must not have New York Heart Association (NYHA) class III or IV heart\n             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or\n             electrocardiographic evidence of acute ischemia\n\n          -  Patients must not have previously existing hypersensitivity to brentuximab vedotin or\n             ipilimumab\n\n          -  Patients must not have a serious medical or psychiatric illness likely to interfere\n             with study participation\n\n          -  Patients must not be participating in any other clinical trial or taking any other\n             experimental medications within 21 days prior to registration\n\n          -  Patients may not receive routine vaccination for infectious disease within 30 days of\n             receiving ipilimumab however it is suggested that routine vaccinations, including\n             seasonal influenza, be given at least 2 weeks prior to study treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896999", 
            "org_study_id": "NCI-2013-01275", 
            "secondary_id": [
                "NCI-2013-01275", 
                "U10CA021115", 
                "E4412", 
                "E4412", 
                "U10CA180820", 
                "U10CA021115"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (ipilimumab and brentuximab vedotin)", 
                "description": "Given IV", 
                "intervention_name": "ipilimumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody", 
                    "MDX-010", 
                    "MDX-CTLA-4", 
                    "monoclonal antibody CTLA-4"
                ]
            }, 
            {
                "arm_group_label": "Treatment (ipilimumab and brentuximab vedotin)", 
                "description": "Given IV", 
                "intervention_name": "brentuximab vedotin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Adcetris", 
                    "anti-CD30 ADC SGN-35", 
                    "anti-CD30 antibody-drug conjugate SGN-35", 
                    "antibody-drug conjugate SGN-35", 
                    "SGN-35"
                ]
            }, 
            {
                "arm_group_label": "Treatment (ipilimumab and brentuximab vedotin)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Cytotoxic T-lymphocyte antigen 4", 
                "Immunoconjugates"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "radvani@stanford.edu", 
                    "last_name": "Ranjana H. Advani", 
                    "phone": "650-725-6456"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Hospitals and Clinics"
                }, 
                "investigator": {
                    "last_name": "Ranjana H. Advani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jonathon.cohen@emory.edu", 
                    "last_name": "Jonathon B. Cohen", 
                    "phone": "404-778-2214"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University/Winship Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jonathon B. Cohen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jonathon B. Cohen", 
                    "phone": "404-778-1868"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University/Winship Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jonathon B. Cohen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jazar@iupui.edu", 
                    "last_name": "Jose M. Azar", 
                    "phone": "317-278-6942"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jose M. Azar", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rambind1@jhmi.edu", 
                    "last_name": "Richard F. Ambinder", 
                    "phone": "410-955-8839"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University/Sidney Kimmel Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Richard F. Ambinder", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Ansell.stephen@mayo.edu", 
                    "last_name": "Stephen M. Ansell", 
                    "phone": "507-284-0923"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Stephen M. Ansell", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Catherine.Diefenbach@nyumc.org", 
                    "last_name": "Catherine S. Diefenbach", 
                    "phone": "212-731-5670"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016-4760"
                    }, 
                    "name": "New York University Clinical Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Catherine S. Diefenbach", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "prmc.coordinator@nyumc.org", 
                    "last_name": "Catherine S. Diefenbach", 
                    "phone": "212-263-4434"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York University Langone Medical Center"
                }, 
                "investigator": {
                    "last_name": "Catherine S. Diefenbach", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tfenske@mcw.edu", 
                    "last_name": "Timothy S. Fenske", 
                    "phone": "414-805-4633"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Froedtert and the Medical College of Wisconsin"
                }, 
                "investigator": {
                    "last_name": "Timothy S. Fenske", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study With an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma", 
        "other_outcome": [
            {
                "description": "These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year vs. those who are event-free at one year will be evaluated.", 
                "measure": "Change in the percentage of activated T cells and natural killer cells", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)"
            }, 
            {
                "description": "These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using the Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year vs. those who are event-free at one year will be evaluated.", 
                "measure": "Change in the percentages of activated T cells and natural killer cells", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of course 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)"
            }, 
            {
                "description": "Pre- and post-treatment levels of these markers will be compared using the Wilcoxon signed-rank test with two-sided type I error of 0.1. Marker levels between patients who fail at 1-year vs. patients who are event-free at 1-year will be evaluated. Given limited data, the analyses of PD-1, co-expression of Tim-3 with PD-1, ICOS, sCD30, galectin-1 and the peripheral blood absolute lymphocyte to monocyte ratio will be mainly exploratory and will be summarized descriptively at the time-points described above. The association with PFS will be explored.", 
                "measure": "Pre- and post-treatment levels of cytokines and T cell specific biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to 6 weeks after completion of study treatment"
            }, 
            {
                "description": "Differentially expressed genes will be identified using a rank-based method developed by Dr. Hong (RankProd, R package, Bioconductor Project) with multiple comparison adjustment using a false discovery rate approach. A two-way unsupervised hierarchical clustering analysis will be applied to both the genes and the samples to illustrate whether GEP can separate two groups or is associated with other clinical factors. The genes ranked as most significant will be assessed by gene ontology and pathway analysis for their potential functions in lymphoma biology and treatment failure.", 
                "measure": "Differentially expressed genes between two groups (patients who fail at 1-year vs. patients who are event-free at 1-year or responders vs. non-responders), assessed using GEP", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "overall_official": {
            "affiliation": "Eastern Cooperative Oncology Group", 
            "last_name": "Catherine Diefenbach", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Upon completion of the trial, frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to CTCAE version 4.0 terminology. Exact 95% confidence intervals around the toxicity proportions will be calculated.", 
            "measure": "MTD of the combination of brentuximab vedotin and ipilimumab defined as the highest dose level at which less than 33% patients experience a DLT, graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
            "safety_issue": "Yes", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reported along with the 95% confidence intervals.", 
                "measure": "CR rate, assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson et al.)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Reported along with the 95% confidence intervals.", 
                "measure": "PR rate, assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson et al.)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Reported along with the 95% confidence intervals.", 
                "measure": "ORR rate, assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson et al.)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "DOR will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy.", 
                "measure": "DOR", 
                "safety_issue": "No", 
                "time_frame": "From the documented beginning of response (CR or PR) to the time of relapse, assessed up to 3 years"
            }, 
            {
                "description": "OS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates.", 
                "measure": "OS", 
                "safety_issue": "No", 
                "time_frame": "From the date of study entry to the date of death, assessed up to 3 years"
            }, 
            {
                "description": "PFS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates.", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "From entry onto study until lymphoma progression or death from any cause, assessed up to 3 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}